Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

572 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Abuse liability for esketamine in a cohort of patients undergoing an acute treatment course to manage treatment-resistant depression: a secondary analysis of an observational study in real-world clinical practicee.
Gutierrez G, Vazquez G, Ravindran N, Lam RW, Giacobbe P, Ganapathy K, Kowara A, Do A, Baskaran A, Nestor SM, Swainson J. Gutierrez G, et al. Among authors: do a. Ther Adv Drug Saf. 2025 Jun 19;16:20420986251347360. doi: 10.1177/20420986251347360. eCollection 2025. Ther Adv Drug Saf. 2025. PMID: 40546784 Free PMC article.
Association of intranasal esketamine, a novel 'standard of care' treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice.
Vazquez G, Gutierrez G, Rosenblat J, Schaffer A, Swainson J, Karthikeyan G, Ravindran N, Lam RW, Do A, Giacobbe P, Hawken E, Milev R. Vazquez G, et al. Among authors: do a. BMJ Open. 2022 Sep 1;12(9):e060967. doi: 10.1136/bmjopen-2022-060967. BMJ Open. 2022. PMID: 36581972 Free PMC article.
IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression.
Gutierrez G, Swainson J, Ravindran N, Lam RW, Giacobbe P, Karthikeyan G, Kowara A, Do A, Baskaran A, Nestor SM, Kang MJY, Biorac A, Vazquez G. Gutierrez G, et al. Among authors: do a. Psychiatry Res. 2024 Oct;340:116125. doi: 10.1016/j.psychres.2024.116125. Epub 2024 Aug 5. Psychiatry Res. 2024. PMID: 39128167 Free article.
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes.
Lam RW, Kennedy SH, Adams C, Bahji A, Beaulieu S, Bhat V, Blier P, Blumberger DM, Brietzke E, Chakrabarty T, Do A, Frey BN, Giacobbe P, Gratzer D, Grigoriadis S, Habert J, Ishrat Husain M, Ismail Z, McGirr A, McIntyre RS, Michalak EE, Müller DJ, Parikh SV, Quilty LC, Ravindran AV, Ravindran N, Renaud J, Rosenblat JD, Samaan Z, Saraf G, Schade K, Schaffer A, Sinyor M, Soares CN, Swainson J, Taylor VH, Tourjman SV, Uher R, van Ameringen M, Vazquez G, Vigod S, Voineskos D, Yatham LN, Milev RV. Lam RW, et al. Among authors: do a. Can J Psychiatry. 2024 Sep;69(9):641-687. doi: 10.1177/07067437241245384. Epub 2024 May 6. Can J Psychiatry. 2024. PMID: 38711351 Free PMC article.
A Randomized Evaluation of MoodFX, a Patient-Centred e-Health Tool to Support Outcome Measurement for Depression: Une évaluation randomisée de MoodFX, un outil de santé en ligne centré sur le patient pour soutenir la mesure du résultat dans la dépression.
Li VW, Sahota J, Dev DK, Gill DD, Evans VC, Axler A, Chakrabarty T, Do A, Keramatian K, Nunez JJ, Tam EM, Yatham LN, Michalak EE, Murphy JK, Lam RW. Li VW, et al. Among authors: do a. Can J Psychiatry. 2024 Jul;69(7):493-502. doi: 10.1177/07067437241245331. Epub 2024 Apr 11. Can J Psychiatry. 2024. PMID: 38600892 Free PMC article. Clinical Trial.
Cariprazine in the Treatment of Bipolar Disorder: Within and Beyond Clinical Trials.
Do A, Keramatian K, Schaffer A, Yatham L. Do A, et al. Front Psychiatry. 2021 Dec 14;12:769897. doi: 10.3389/fpsyt.2021.769897. eCollection 2021. Front Psychiatry. 2021. PMID: 34970166 Free PMC article. Review.
Although current pharmacological treatments for BD have improved its clinical management, many patients do not achieve remission, particularly those suffering from bipolar depression. In addition, available treatments are associated with a myriad of potential advers …
Although current pharmacological treatments for BD have improved its clinical management, many patients do not achieve remission, par …
572 results